MWNA
INDP icon

Marshall Wace North America’s Indaptus Therapeutics INDP Stock Holding History

Marshall Wace North America’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7
Closed -$117K – 1349
2019
Q1 		$117K Buy
+7
New +$123K ﹤0.01% 1089

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace North America's INDP Position: Q2 2019 in Review

Marshall Wace North America sold out of Indaptus Therapeutics (INDP) in Q2 2019, closing a stake of 7 shares — an estimated $117K sold.

Marshall Wace North America first reported a position in INDP in Q1 2019 and held it in 1 quarter. The position peaked at $117K in Q1 2019. 47 funds tracked by Wall St. Rank hold INDP as of Q2 2019.

  • Marshall Wace North America reported no remaining Indaptus Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 7 Indaptus Therapeutics shares in Q2 2019, an estimated $117K.
  • Marshall Wace North America first reported a position in Indaptus Therapeutics in Q1 2019 and held it in 1 quarter.
  • Marshall Wace North America's Indaptus Therapeutics position peaked at $117K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.